VNDA (Vanda Pharmaceuticals) Inventories, Finished Goods: $1.7 Mil (As of Mar. 2026)


VNDA Vanda Pharmaceuticals Inc VNDA
73 GF Score
Price $6.24
GF Value $5.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Inventories, Finished Goods?

Vanda Pharmaceuticals VNDA -2.19% 73 Inventories, Finished Goods is $1.7 Mil as of Mar. 2026. GuruFocus rates VNDA with a GF Score™ of 73/100 and a GF Value™ of $5.54 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Vanda Pharmaceuticals's quarterly finished goods declined from Sep. 2025 ($2.0 Mil) to Dec. 2025 ($1.9 Mil) and declined from Dec. 2025 ($1.9 Mil) to Mar. 2026 ($1.7 Mil).

Vanda Pharmaceuticals's annual finished goods increased from Dec. 2023 ($1.3 Mil) to Dec. 2024 ($1.7 Mil) and increased from Dec. 2024 ($1.7 Mil) to Dec. 2025 ($1.9 Mil).

Vanda Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Inventories, Finished Goods Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 1.17 1.33 1.73 1.85

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 2.17 2.04 1.85 1.70
VNDA
73GF Score
Vanda Pharmaceuticals Inc VNDA
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $1.7 Mil mean?
Vanda Pharmaceuticals (VNDA) has a Inventories, Finished Goods of $1.7 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Inventories, Finished Goods too high?
Vanda Pharmaceuticals' current Inventories, Finished Goods is $1.7 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Inventories, Finished Goods compare to AVIR and OABI?
Vanda Pharmaceuticals' Inventories, Finished Goods of $1.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Inventories, Finished Goods is $1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.54, compared to a current price of $6.24 — trading 12.6% above its estimated fair value. The current Inventories, Finished Goods is $1.7 Mil. Vanda Pharmaceuticals' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Inventories, Finished Goods is $1.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $6.24 is trading 12.6% above its estimated GF Value™ of $5.54. GuruFocus considers Vanda Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for VNDA:

  • Inventories, Finished Goods: $1.7 Mil
  • GF Value™: $5.54 vs. price of $6.24 (12.6% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
73GF Score

Get the complete analysis for VNDA

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price
$5.54
GF Value